Allogeneic mesenchymal stromal cells    (DrugBank: Mesenchymal Stromal Cells)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
36表皮水疱症3

36. 表皮水疱症 [臨床試験数:147,薬物数:170(DrugBank:40),標的遺伝子数:32,標的パスウェイ数:113
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 147 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02323789
(ClinicalTrials.gov)
June 201518/12/2014Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis BullosaA Phase I/II Study Evaluating Allogeneic Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDrug: Mesenchymal stromal cellsKing's College LondonNULLActive, not recruiting18 Years65 YearsAll10Phase 1/Phase 2United Kingdom
2EUCTR2014-004500-30-GB
(EUCTR)
13/02/201522/12/2014A prospective phase I/II study to evaluate the use of mesenchymal stromal (stem) cells for the treatment of skin disease in adults with recessive dystrophic epidermolysis bullosa A phase I/II study evaluating allogeneic mesenchymal stromal cells in adults with recessive dystrophic epidermolysis bullosa - ADSTEM Recessive dystrophic epidermolysis bullosa;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]King's College LondonGuy's and St Thomas NHS Foundation TrustNot Recruiting Female: yes
Male: yes
10 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
3EUCTR2012-001394-87-GB
(EUCTR)
16/11/201222/08/2012A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. - EBSTEM Recessive Dystrophic Epidermolysis Bullosa
MedDRA version: 17.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Allogenic mesenchymal stromal cells
Product Code: TC-MSC
King's College LondonNULLNot RecruitingFemale: yes
Male: yes
10Phase 1;Phase 2United Kingdom